Physician profile
Robert Stokes
NPI 1225136633
$3,587.36
in general payments reported to CMS, 2019-2025
23 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $65.95 · 2021: $351 · 2022: $899 · 2023: $656 · 2024: $781 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Education: $13.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.24 |
| Education | $13.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.04 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $703.31 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.90 | 2019-2024 | Xifaxan |
| Genzyme Corporation | $151.26 | 2022-2024 | |
| Madrigal Pharmaceuticals | $142.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Fujifilm Healthcare Americas Corporation | $101.12 | 2022 | |
| Celgene Corporation | $94.58 | 2022-2023 | Zeposia |
| Medtronic USA, INC. | $79.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.18 | 2022-2025 | Eohilia |
| Phathom Pharmaceuticals, INC. | $50.72 | 2024-2025 | Voquezna |
| Pfizer INC. | $43.73 | 2019 | |
| Braintree Laboratories, INC. | $40.37 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $39.53 | 2023-2025 | Ocaliva |
| Shire North American Group INC | $36.99 | 2019 | |
| Celltrion USA INC. | $35.95 | 2024-2025 | Vegzelma, Zymfentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $33.27 | 2019 | |
| Avanos Medical | $25.74 | 2019 | |
| Ardelyx, INC. | $23.89 | 2024 | Ibsrela |
| Medtronic, INC. | $23.47 | 2025 | Interstim |
| Gilead Sciences, INC. | $22.69 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.17 | 2022 | |
| Daiichi Sankyo INC. | $18.28 | 2021 | |
| Aimmune Therapeutics, INC. | $17.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.